Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 24;12:753319. doi: 10.3389/fimmu.2021.753319

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Sablerolles, Goorhuis, GeurtsvanKessel, de Vries, Huckriede, Koopmans, Lafeber, Postma, van Baarle, Visser, Dalm, Kootstra, Rietdijk and van der Kuy

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

SWITCH trial design. The SWITCH trial includes four arms that receive a booster vaccination 84 days after prime with Ad26.COV2.S. Blood samples will be collected at indicated timepoints by venepunctures. Questionnaires will be performed to collect reactogenicity data and to determine whether participants had breakthrough infections despite vaccinations. *One of the four arms or 25% of the randomized participants will not receive a second vaccination; **Unblinding the randomization of participants will be done after the side effects (i.e., reactogenicity) questionnaire is completed.